Buys | $165,941 | 9 | 90 |
Sells | $29,583 | 1 | 10 |
Duey Marc | director | 2 | $132,190 | 1 | $29,583 | $102,607 |
Seizinger Bernd R. | director | 1 | $26,800 | 0 | $0 | $26,800 |
Gilad Oren | President/CEO | 4 | $5,654 | 0 | $0 | $5,654 |
Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 2 | $1,298 | 0 | $0 | $1,298 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $165,941 and sold $29,583 worth of Aprea Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $162,430 and sold $31.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Duey Marc (director) — $132,190. Seizinger Bernd R. (director) — $26,800. Gilad Oren (President/CEO) — $5,654.
The last purchase of 500 shares for transaction amount of $1,958 was made by Gilad Oren (President/CEO) on 2024‑10‑23.
2024-10-23 | Gilad Oren | President/CEO | 500 0.0086% | $3.92 | $1,958 | -13.59% | ||
2024-10-18 | Sale | Duey Marc | director | 6,462 0.1238% | $4.58 | $29,583 | -22.39% | |
2024-10-16 | Duey Marc | director | 30,000 0.8303% | $4.39 | $131,700 | -2.14% | ||
2024-10-15 | Gilad Oren | President/CEO | 250 0.0046% | $2.90 | $725 | +12.46% | ||
2024-10-14 | Gilad Oren | President/CEO | 1,000 0.0163% | $2.59 | $2,590 | +33.79% | ||
2024-10-14 | Duey Marc | director | 190 0.0031% | $2.58 | $490 | +33.79% | ||
2024-10-11 | Seizinger Bernd R. | director | 10,000 0.169% | $2.68 | $26,800 | +31.54% | ||
2024-10-11 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 50 0.0008% | $2.46 | $123 | +31.54% | ||
2024-10-10 | Gilad Oren | President/CEO | 150 0.0024% | $2.54 | $381 | +34.45% | ||
2024-10-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 450 0.0074% | $2.61 | $1,175 | +34.45% | ||
2024-03-13 | Gilad Oren | President, CEO | 2,000 0.0683% | $7.29 | $14,580 | -31.53% | ||
2024-03-13 | Seizinger Bernd R. | director | 6,860 0.2342% | $7.29 | $50,009 | -31.53% | ||
2024-03-13 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 1,010 0.0345% | $7.29 | $7,363 | -31.53% | ||
2024-03-13 | HENNEMAN JOHN B III | director | 6,860 0.2342% | $7.29 | $50,009 | -31.53% | ||
2023-06-07 | Seizinger Bernd R. | director | 6,029 0.1917% | $3.68 | $22,192 | +18.87% | ||
2023-06-06 | Seizinger Bernd R. | director | 4,068 0.1208% | $3.63 | $14,764 | +11.20% | ||
2020-12-28 | Sale | Redmile Group, LLC | 10 percent owner | 500,000 2.4014% | $5.58 | $2.79M | -11.73% | |
2020-10-05 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 175,000 0.7844% | $25.30 | $4.43M | -80.91% | |
2020-07-07 | Sale | KDev Investments AB | 10 percent owner | 241,703 1.1593% | $34.55 | $8.35M | -79.65% | |
2020-06-16 | Sale | ROCKLAGE SCOTT M | Former 10% holder | 120,164 0.5556% | $33.30 | $4M | -38.45% |
Gilad Oren | President/CEO | 333395 6.1343% | $796,814.05 | 5 | 0 | <0.0001% |
Duey Marc | director | 233651 4.2991% | $558,425.89 | 2 | 1 | |
Seizinger Bernd R. | director | 44730 0.823% | $106,904.70 | 4 | 0 | <0.0001% |
Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 19368 0.3564% | $46,289.52 | 3 | 0 | <0.0001% |
Christenson Johan | director | 2366104 43.5354% | $5.65M | 1 | 0 | +53.58% |
HealthCap VII, L.P. | 10 percent owner | 2366104 43.5354% | $5.65M | 1 | 0 | +53.58% |
KDev Investments AB | 10 percent owner | 1992586 36.6628% | $4.76M | 0 | 2 | |
Redmile Group, LLC | 10 percent owner | 1768718 32.5437% | $4.23M | 1 | 1 | +53.58% |
Versant Vantage I, L.P. | 10 percent owner | 333333 6.1332% | $796,665.87 | 1 | 0 | +53.58% |
Versant V Luxco S.a r.l. | 10 percent owner | 333333 6.1332% | $796,665.87 | 1 | 0 | +53.58% |
5AM Ventures IV, L.P. | Former 10% holder | 138497 2.5483% | $331,007.83 | 1 | 4 | +53.58% |
ROCKLAGE SCOTT M | Former 10% holder | 75965 1.3977% | $181,556.35 | 0 | 3 | |
HENNEMAN JOHN B III | director | 8139 0.1498% | $19,452.21 | 2 | 0 | +11.02% |
Magni Guido | director | 6500 0.1196% | $15,535.00 | 1 | 0 | +53.58% |
SCHADE CHRISTIAN S | President & CEO | 5000 0.092% | $11,950.00 | 1 | 0 | +53.58% |
Coiante Scott M | SVP, Chief Financial Officer | 2500 0.046% | $5,975.00 | 1 | 0 | +53.58% |
Korbel Gregory Alan | VP of Business Dev't | 500 0.0092% | $1,195.00 | 1 | 0 | +53.58% |
Attar Eyal C. | SVP, Chief Medical Officer | 200 0.0037% | $478.00 | 1 | 0 | +53.58% |
$8,253,997 | 122 | -53.40% | $12.32M | |
$992,222,850 | 90 | -12.52% | $12.4M | |
$1,724,269 | 63 | -16.36% | $12.18M | |
$8,900,811 | 57 | -24.79% | $13.53M | |
$296,936 | 37 | -18.12% | $13.91M | |
$383,884 | 32 | -25.10% | $13.89M | |
$95,303,339 | 30 | -13.78% | $12.59M | |
$86,569,038 | 18 | -12.64% | $11.53M | |
$114,371,781 | 18 | -1.31% | $12.97M | |
$112,810,270 | 18 | -1.20% | $13.39M | |
Aprea Therapeutics, Inc. (APRE) | $29,469,413 | 18 | 30.38% | $12.99M |
$122,973 | 15 | -26.96% | $12.36M | |
$490,284 | 15 | -19.03% | $10.39M | |
$941,975 | 12 | -10.74% | $12.19M | |
$389,864 | 11 | 12.52% | $14.5M | |
$36,538,405 | 10 | -21.99% | $15.07M | |
$38,247,728 | 10 | -10.97% | $13.9M | |
$11,777,042 | 10 | -11.94% | $13.06M | |
$2,891,537 | 8 | -39.31% | $13.82M |
Increased Positions | 10 | +47.62% | 87,793 | +4.39% |
Decreased Positions | 5 | -23.81% | 11,500 | -0.57% |
New Positions | 5 | New | 64,455 | New |
Sold Out Positions | <1 | Sold Out | 899 | Sold Out |
Total Postitions | 26 | +23.81% | 2M | +3.81% |
Aigh Capital Management Llc | $1,294.00 | 10.79% | 539,300 | 0 | 0% | 2024-12-31 |
Sio Capital Management, Llc | $664.00 | 5.53% | 276,603 | 0 | 0% | 2024-12-31 |
Sphera Funds Management Ltd. | $648.00 | 5.4% | 270,000 | 0 | 0% | 2024-12-31 |
Nantahala Capital Management, Llc | $494.00 | 4.12% | 205,760 | 0 | 0% | 2024-12-31 |
Vanguard Group Inc | $417.00 | 3.48% | 173,842 | 0 | 0% | 2024-12-31 |
Stonepine Capital Management, Llc | $358.00 | 2.98% | 149,221 | +12,047 | +8.78% | 2024-12-31 |
Dafna Capital Management Llc | $329.00 | 2.74% | 137,174 | 0 | 0% | 2024-12-31 |
Exome Asset Management Llc | $307.00 | 2.56% | 127,960 | -9,214 | -6.72% | 2024-12-31 |
Geode Capital Management, Llc | $102.00 | 0.85% | 42,663 | +2,596 | +6.48% | 2024-12-31 |
Morgan Stanley | $88.00 | 0.74% | 36,808 | +2,600 | +7.6% | 2024-12-31 |